Literature DB >> 11152795

Repositioning accuracy with the Laitinen frame for fractionated stereotactic radiation therapy in adult and pediatric brain tumors: preliminary report.

J A Kalapurakal1, Z Ilahi, A G Kepka, T Bista, S Goldman, T Tomita, M H Marymont.   

Abstract

PURPOSE: To determine the repositioning accuracy, patient tolerance, and clinical efficacy of stereotactic radiation therapy for brain tumors in children and adults performed with the Laitinen stereotactic localizer and head holder.
MATERIALS AND METHODS: In this retrospective analysis, stereotactic frame tolerance was assessed by recording patient discomfort or pain in the ear and nose during each treatment in 34 patients, including 21 children and 13 adults with 37 lesions treated with fractionated stereotactic radiation therapy. Radiation doses ranged from 10-60 Gy at 1.0-4.0 Gy per fraction. Repositioning accuracy was assessed by comparing portal radiographs with setup fields on computed tomographic (CT) scout images. Clinical efficacy was assessed by analyzing posttreatment CT and magnetic resonance images.
RESULTS: The stereotactic localizer was well tolerated. The mean isocenter shifts observed after studying 305 portal radiographs were x-coordinate shift of 1.0 mm +/- 0.7 (SD), y-coordinate shift of 0.8 mm +/- 0.8, and z-coordinate shift of 1.7 mm +/- 1.0. At a median follow-up of 16 months, local control was achieved in 18 of 22 primary and in one of eight of recurrent tumors.
CONCLUSION: The Laitinen stereotactic localizer is well tolerated with accurate reproducibility during stereotactic radiation therapy. Preliminary local control rates are consistent with those in other reports.

Entities:  

Mesh:

Year:  2001        PMID: 11152795     DOI: 10.1148/radiology.218.1.r01ja23157

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  7 in total

1.  Rotational and translational reproducibility of newly developed Leksell frame-based relocatable fixation system.

Authors:  Etsuo Kunieda; Hossain M Deloar; Masayuki Kitamura; Osamu Kawaguchi; Hideyuki Shiba; Atsuya Takeda; Takatsugu Kawase; Satoshi Seki; Naoyuki Shigematsu; Atsushi Kubo
Journal:  Radiat Med       Date:  2006-08

2.  Relocatable fixation systems in intracranial stereotactic radiotherapy. Accuracy of serial CT scans and patient acceptance in a randomized design.

Authors:  A Theelen; J Martens; G Bosmans; R Houben; J J Jager; I Rutten; P Lambin; A W Minken; B G Baumert
Journal:  Strahlenther Onkol       Date:  2011-12-24       Impact factor: 3.621

Review 3.  Radiation therapy in the management of pediatric craniopharyngiomas--a review.

Authors:  John A Kalapurakal
Journal:  Childs Nerv Syst       Date:  2005-06-17       Impact factor: 1.475

4.  Analysis of patient repositioning accuracy in precision radiation therapy using automated image fusion.

Authors:  James L Robar; Brenda G Clark; Jason W Schella; Chang Seon Kim
Journal:  J Appl Clin Med Phys       Date:  2005-01-12       Impact factor: 2.102

5.  Six degrees of freedom CBCT-based positioning for intracranial targets treated with frameless stereotactic radiosurgery.

Authors:  Anees Dhabaan; Eduard Schreibmann; Arsalan Siddiqi; Eric Elder; Tim Fox; Tomi Ogunleye; Natia Esiashvili; Walter Curran; Ian Crocker; Hui-Kuo Shu
Journal:  J Appl Clin Med Phys       Date:  2012-11-08       Impact factor: 2.102

6.  Accuracy of relocation, evaluation of geometric uncertainties and clinical target volume (CTV) to planning target volume (PTV) margin in fractionated stereotactic radiotherapy for intracranial tumors using relocatable Gill-Thomas-Cosman (GTC) frame.

Authors:  Saikat Das; Rajesh Isiah; B Rajesh; B Paul Ravindran; Rabi Raja Singh; Selvamani Backianathan; J Subhashini
Journal:  J Appl Clin Med Phys       Date:  2010-12-28       Impact factor: 2.102

7.  Fractionated stereotactic radiotherapy for pediatric patients with retinoblastoma.

Authors:  Patrick D Higgins; Bruce J Gerbi; Mark Macedon; Kathryn E Dusenbery
Journal:  J Appl Clin Med Phys       Date:  2006-05-25       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.